Loading
Latest filing published 03 Apr 2026 for 셀트리온제약, €33.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
양지석 (chief executive) discloses dealings in 셀트리온제약 to DART (FSS). Over a trading history stretching from 26 March 2024 to 24 March 2026, the count stands at 3 filings.
Every open-market trade on record is a purchase: 3 purchases worth €106, and no sale. The totals exclude 1 filing filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2026 alone, the filings show 1 purchase and no sales.
The record was last updated on 3 April 2026 with an open-market purchase (€33) in 셀트리온제약. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations